Loading...
•
Dec 31, 2023
4DMT Q4 2023 Earnings Report
Reported full year 2023 financial results and provided operational highlights.
Key Takeaways
4D Molecular Therapeutics reported a transformative year in 2023, marked by significant progress in its product pipeline and platform across multiple therapeutic areas. The company highlighted positive interim data from the Phase 2 PRISM study of 4D-150 in wet AMD, advancements in clinical trials for 4D-710 in cystic fibrosis and 4D-310 in Fabry disease, and strategic agreements with Astellas Pharma and Arbor Biotechnologies. 4DMT's cash position was strengthened by a completed public follow-on offering, extending its operational runway into the first half of 2027.
Presented positive interim data from the Phase 2 PRISM study of 4D-150 in wet AMD, enabling Phase 3 pivotal development.
Demonstrated positive interim clinical data for 4D-710 in cystic fibrosis and 4D-310 in Fabry disease.
Secured strategic agreements with Astellas Pharma in rare monogenic retinal diseases and Arbor Biotechnologies in CNS gene editing.
Completed an upsized public follow-on offering, supplementing cash position and extending operational runway into the first half of 2027.
4DMT
4DMT
4DMT Revenue by Segment
Revenue by Segment
Collaboration & license rev. Revenue
CapyFin.com Forward Guidance
4DMT anticipates several milestones in the near future across its key programs.
Positive Outlook
- Initial interim 24-week landmark analysis for Phase 2 PRISM Population Extension cohort of 4D-150 for Wet AMD expected in Q3 2024.
- Additional FDA and EMA regulatory interactions for 4D-150 planned in Q2 2024, with an update expected in Q3 2024.
- Phase 3 clinical trial initiation for 4D-150 for Wet AMD expected in Q1 2025.
- Initial interim 24-week landmark data for Phase 2 SPECTRA clinical trial Dose Confirmation cohort of 4D-150 for DME expected in H2 2024.
- FDA submission of preclinical NHP safety data for 4D-310 for Fabry Disease Cardiomyopathy in combination with rituximab/sirolimus immunosuppression regimen expected in Q2 2024.